{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:53:03Z","timestamp":1758819183444},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T00:00:00Z","timestamp":1402444800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00280-014-2493-x","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T15:37:40Z","timestamp":1402414660000},"page":"419-426","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies"],"prefix":"10.1007","volume":"74","author":[{"given":"Andrea","family":"Wang-Gillam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Baggstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Naughton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuntian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibu","family":"Mwandoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Trull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison N.","family":"Creekmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,11]]},"reference":[{"issue":"3","key":"2493_CR1","first-page":"479","volume":"10","author":"A Janus","year":"2005","unstructured":"Janus A, Robak T, Smolewski P (2005) The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10(3):479\u2013498","journal-title":"Cell Mol Biol Lett"},{"issue":"22","key":"2493_CR2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281. doi: 10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"key":"2493_CR3","doi-asserted-by":"crossref","unstructured":"Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C (2000) Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Reprinted from Biotechnology and Bioengineering, Vol. XI, Issue 6, Pages 1101\u20131110 (1969). Biotechnol Bioeng 67(6):704\u2013713","DOI":"10.1002\/(SICI)1097-0290(20000320)67:6<704::AID-BIT8>3.0.CO;2-L"},{"issue":"Suppl 4","key":"2493_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2165\/00003495-199700544-00006","volume":"54","author":"FM Muggia","year":"1997","unstructured":"Muggia FM (1997) Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 54(Suppl 4):22\u201329","journal-title":"Drugs"},{"issue":"14","key":"2493_CR5","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"4","key":"2493_CR6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1995.13.4.914","volume":"13","author":"M Harrison","year":"1995","unstructured":"Harrison M, Tomlinson D, Stewart S (1995) Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol 13(4):914\u2013920","journal-title":"J Clin Oncol"},{"issue":"9","key":"2493_CR7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","volume":"9","author":"SL Abrams","year":"2010","unstructured":"Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Basecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA (2010) The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9(9):1781\u20131791","journal-title":"Cell Cycle"},{"issue":"1","key":"2493_CR8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/CAD.0b013e3283400a20","volume":"22","author":"T O\u2019Reilly","year":"2011","unstructured":"O\u2019Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA (2011) Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22(1):58\u201378. doi: 10.1097\/CAD.0b013e3283400a20","journal-title":"Anticancer Drugs"},{"issue":"21","key":"2493_CR9","first-page":"6141","volume":"62","author":"V Grunwald","year":"2002","unstructured":"Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62(21):6141\u20136145","journal-title":"Cancer Res"},{"issue":"4","key":"2493_CR10","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987\u2013992","journal-title":"Cancer Res"},{"issue":"5","key":"2493_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42(5):419\u2013436","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2493_CR12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ijc.28083","volume":"133","author":"KA Thornton","year":"2013","unstructured":"Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM (2013) A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer 133(4):997\u20131005. doi: 10.1002\/ijc.28083","journal-title":"Int J Cancer"},{"issue":"4","key":"2493_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-3083.1996.d01-52.x","volume":"43","author":"BR Yacyshyn","year":"1996","unstructured":"Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM (1996) Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 43(4):449\u2013455","journal-title":"Scand J Immunol"},{"issue":"11","key":"2493_CR14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/sj.bjc.6604376","volume":"98","author":"JP Boni","year":"2008","unstructured":"Boni JP, Leister C, Burns J, Hug B (2008) Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 98(11):1797\u20131802. doi: 10.1038\/sj.bjc.6604376","journal-title":"Br J Cancer"},{"issue":"1","key":"2493_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2011.06.005","volume":"311","author":"S Gaur","year":"2011","unstructured":"Gaur S, Chen L, Yang L, Wu X, Un F, Yen Y (2011) Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. Cancer Lett 311(1):20\u201328. doi: 10.1016\/j.canlet.2011.06.005","journal-title":"Cancer Lett"},{"issue":"21","key":"2493_CR16","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1158\/1078-0432.CCR-11-0666","volume":"17","author":"JW Moroney","year":"2011","unstructured":"Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R (2011) A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17(21):6840\u20136846. doi: 10.1158\/1078-0432.ccr-11-0666","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2493-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2493-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2493-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T07:43:03Z","timestamp":1565509383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2493-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,11]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2493"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2493-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,11]]}}}